The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Agreed, would have expected a bit more revenue but at least it's an increase compared to previous year.
It's a relatively no surprises set of results - strong and consistent. And I would expect a churn in the stock as a positive.
DYOR
Interesting contract announcement with a white label approach. Could MHC go down the same route with their products, or be pushed out?
DYOR
The SP is slipping a bit lower than I would like, but expected due to no recent updates.
There is an interesting podcast on the UK Investor Magazine featuring investor & analyst Charles Archer. If you have a listen to the final 5 minutes, HVO is covered.
DYOR
It's a shame this thread is all about trying to get one over on the previous comment etc. It's like a battle of egos.
Perhaps we can get back to fundamentals and the real reason we are here, which is to make money for ourselves and not get bothered about what goes on outside of that circle of influence.
I can see the SP drifting around the support level of 25-26p for a while until we see the finals, dividend confirmation, contract announcements or small M&A as has been mentioned previously.
DYOR
DYOR